TMCnet News

PixarBio CEO Frank Reynolds to Be Honored with 2014 Irish Education 100 Award Following Nomination by St. Joseph's University
[November 20, 2014]

PixarBio CEO Frank Reynolds to Be Honored with 2014 Irish Education 100 Award Following Nomination by St. Joseph's University


MEDFORD, Mass. --(Business Wire)--

PixarBio Corporation is pleased to announce that its CEO Frank Reynolds will receive the prestigious 2014 Irish Education 100 Award, a listing of leading figures in education across the United States.

The Irish Consul General will hold a special celebration next month in New York City to honor all inductees. "I am extremely proud to be included in this extraordinary list of Irish-Americans who have recognized the power knowledge can bring to new generations," says Frank Reynolds. "There is no doubt that formal education, and a lot of it, has provided me with the foundation for my success. There is no more logical cause for me than to give back to the universities that have paved my path to success and to ensure those pathways to success remain open to all. want to thank St. Joseph's University and Jim Scott from the Association for Disabled Students for assisting me in completing my education and I'd like to thank Christine Hartman, Director of Graduate Education, for my nomination. Their spirit exemplifies the hawk never dies."



The Irish Education 100 gives tribute to the enduring Irish success in education, especially at the university level. It was first compiled in 2009 by the Irish Voice newspaper in an effort to quantify the Irish commitment to excellence in education in the United States. This year's listing featuring the 2014 Irish Education 100 honorees will appear in a special edition issue of the Irish Voice on December 17.

About PixarBio Corporation


PixarBio Corporation is dedicated to developing new therapeutic options for Parkinson's disease, epilepsy, pain, and spinal cord injury. Cofounded by Frank Reynolds, Dr. Robert S. Langer from MIT's (News - Alert) Langer Lab and Katrin Holzhaus, the company is developing novel smart materials to achieve sustained release of agents. Research is focused on a platform for chronic neurological applications. For more information visit www.pixarbio.com.


[ Back To TMCnet.com's Homepage ]